ResMed (NYSE: RMD), a leading global name within the bio-tech market, has been in focus for its strong performance and financial fundamentals. Stake increases by both
Park Avenue Securities LLC and
Wellington Management Group LLP highlight the company's attractive potential for institutional investors. Moreover, investors have seen substantial returns, with a
377% increase over the past five years and a
101% return recently. Despite a drop due to Eli Lilly’s clinical trials for a weight-loss drug that could reduce sleep apnea events, ResMed's Q3 earnings and revenues have exceeded estimates showing
strong growth, consequently increasing its momentum. The debut of their new
AirCurve 11 device and smallest full-face CPAP Mask,
AirFit F40, further solidifies ResMed's commitment to treating sleep apnea. ResMed’s earning results for Q2 and Q3 FY2024 significantly surpassed estimates, showing resilient expansion in a growing global market. Investment platform
Zacks.com has highlighted ResMed for its strong earnings in Q3, while Needham & Company LLC has reiterated a 'Buy' rating. Despite a recent downgrade to 'Market Perform' at Oppenheimer and by Citigroup to 'Neutral',
ResMed remains a favoured stock among investors.
Resmed RMD News Analytics from Wed, 24 Jan 2024 08:00:00 GMT to Sun, 30 Jun 2024 09:46:37 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -3
